Lightning-Fast Speeds, Massive Capacities: Crucial SSDs Elevate Gaming and Creative Endeavors
The Crucial T710 sets a new standard with unparalleled Gen5 performance for pro gamers and creators.
The Crucial X10 portable SSD combines sleek style, functional durability and storage options up to 8TB.
TAIPEI, Taiwan, May 19, 2025 (GLOBE NEWSWIRE) -- Today at Computex 2025, Micron Technology, Inc. (Nasdaq: MU) expanded its leadership in consumer storage by unveiling its latest high-performance SSDs — the Crucial T710 PCIe Gen5 NVMe SSD and the Crucial X10 Portable SSD. Forged from years of dedicated research and development, these next-gen SSDs redefine performance standards across the board by pushing the limits of speed, capacity and durability — powering your world at full speed.
'Our fastest Gen5 drive yet, the Crucial T710 SSD turbocharges gaming and creative applications,' said Dinesh Bahal, corporate vice president and general manager of Micron's Commercial Products Group. 'Meanwhile, our X10 portable drive is a powerhouse, effortlessly handling massive backups, games and photo libraries — no matter where life takes you or what it throws your way. These innovations from Crucial underscore our relentless effort to exceed our customers' storage needs.'A Media Snippet accompanying this announcement is available by clicking on this link.
Crucial T710: Blazing fast Gen5 speed for gaming and AI
Leveraging cutting-edge NVMe technology and Micron's G9 NAND, the Crucial T710 delivers unmatched Gen5 performance for pro-level gaming, creative applications and data-intensive tasks like AI. Boasting our best Gen5 speeds to date, it features up to:
14,900 megabytes per second (MB/s) sequential read speeds1
13,800 MB/s sequential write speeds1
2.2 million random read speeds1
2.3 million random write speeds 1
The T710 delivers up to 67% more IOPs per watt than previous-generation Gen5 drives, running faster and cooler and making it ideal for PCs, laptops and workstations. The optional integrated heatsink ensures the T710 stays cool under pressure and capacity options up to 4TB2 means users have the storage space they need for their most demanding projects.
The increasing demands of AI applications require robust hardware for optimal performance. With its dramatically increased energy efficiency and decreased latency, the Crucial T710 is perfect for enabling real-time local data processing on AI PCs, with the speed to load a large language model from SSD to memory in under one second.3
Crucial X10: Fast and tough portable storage to expand your digital life
Crucial's latest portable drive, the X10, delivers read speeds of up to 2,100 MB/s,4 twice as fast as its predecessor.5 The X10 is designed for users who need a fast, reliable and durable solution to back up and store their most important photos, games, movies, documents and more. With 4TB, 6TB and 8TB6 versions available, the Crucial X10 allows users to store massive amounts of data, including up to 500,000 4K photos, 114 games or 2.6 million MP3 files7.
With its sleek, matte blue design, the X10 is perfect for content creators, gamers, photography hobbyists and mainstream consumers who require high-speed data transfer and ample storage capacity. Its durable design is IP65 dust- and water-resistant and drop-resistant up to 9.8 feet,8 making it a vault for your data — secure, portable and always ready.
The T710 uses Silicon Motion's SM2508 controller, while the X10 uses the SM2322 controller.
'To meet the evolving demands of next-generation AI PCs, we've engineered our industry-leading SM2508 controller to deliver game-changing Gen5 performance combined with significant power savings compared to competitors,' said Nelson Duann, senior vice president of Silicon Motion's Client & Automotive Storage Business. 'Our close technical collaboration with Micron to turbocharge the Crucial T710 will transform the latest notebooks with extreme Gen5 performance that meets the needs of intensive applications like AI, gaming and beyond.'
Availability: The Crucial X10 is now available for purchase through etailers, retailers and global channel partners, while T710 will be available starting in July 2025.
Additional Resources:
Crucial X10 web page
Crucial T710 web page
About Micron Technology, Inc.
Micron Technology, Inc. is an industry leader in innovative memory and storage solutions, transforming how the world uses information to enrich life for all. With a relentless focus on our customers, technology leadership, and manufacturing and operational excellence, Micron delivers a rich portfolio of high-performance DRAM, NAND, and NOR memory and storage products through our Micron® and Crucial® brands. Every day, the innovations that our people create fuel the data economy, enabling advances in artificial intelligence (AI) and compute-intensive applications that unleash opportunities — from the data center to the intelligent edge and across the client and mobile user experience. To learn more about Micron Technology, Inc. (Nasdaq: MU), visit micron.com.
© 2025 Micron Technology, Inc. All rights reserved. Information, products, and/or specifications are subject to change without notice. Micron, the Micron logo, and all other Micron trademarks are the property of Micron Technology, Inc. All other trademarks are the property of their respective owners.
1 Typical I/O performance as measured using CrystalDiskMark® with a queue depth of 512 and write cache enabled. Windows 11 Core isolation disabled for performance measurement. Fresh out-of-box (FOB) state is assumed. For performance measurement purposes, the SSD may be restored to FOB state using the secure erase command. System variations will affect measured results.
2 Some storage capacity is used for formatting and other purposes and is not available for data storage. 1GB equals 1 billion bytes.
3 As tested in Micron labs using Llama 2 with 13 billion parameters,10.4GB file size and 6-bit quantization vs. the PCIe Gen4 Micron 3500 SSD.
4 MB/s speed measured by Crucial as maximum sequential performance of device on a high-performance desktop computer with Crystal Disk Mark (version 8.0.4 for x64). Your performance may vary.
5 Comparative speed claims measured against maximum reported speeds from Crucial X9 SSD. Your performance may vary.
6 Some storage capacity is used for formatting and other purposes and is not available for data storage. 1GB equals 1 billion bytes.
7 Based on average photo size of 6MB, video at 4K/60fps in H264 format at 24GB/hr and 200GB for AAA games.
8 Up to 3 meters without impact to data on a carpeted floor.
CONTACT: Micron Media Relations Contact Mengxi Liu Evensen +1 (408) 444-2276 productandtechnology@micron.com Micron Investor Relations Contact Satya Kumar +1 (408) 450-6199 satyakumar@micron.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
Data Highlights Transformative Promise of CAR T in Solid Tumors Phase 1 Trial with ALLO-316 Demonstrated Potential to Provide Meaningful Clinical Benefit in Patients with CD70 TPS ≥ 50% Advanced or Metastatic RCC A Single Dose of ALLO-316 Achieved a 31% Confirmed Response Rate Four of Five Confirmed Responders Remain in Response Including One Ongoing Remission Over 12 Months Robust Expansion, Persistence, and Tumor Infiltration of ALLO-316 Seen with Standard Lymphodepletion, Showcasing Dagger® Technology as a Next-Generation Allogeneic Platform Phase 1 Safety Profile was Manageable; Proactive Diagnostic and Management Strategies Proved Effective in Mitigating IEC-HS While Preserving Efficacy SOUTH SAN FRANCISCO, Calif., June 01, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, presented updated data from the Phase 1 TRAVERSE study of ALLO-316 in renal cell carcinoma (RCC) during an oral presentation at the 2025 ASCO Annual Meeting. The Phase 1 TRAVERSE trial enrolled patients with advanced or metastatic renal cell RCC. Leveraging the proprietary Dagger® technology to enable robust CAR T cell expansion, it stands as the first and only allogeneic CAR T product to show promise in treating solid tumors. The presentation focused on the Phase 1b expansion cohort from the Phase 1 TRAVERSE study in which patients were treated with a standard regimen of cyclophosphamide and fludarabine followed by a single dose of 80 million AlloCAR T™ cells. 'ALLO-316 is showing clear evidence of targeted antitumor activity in patients who had failed most or all approved therapies for advanced or metastatic renal cell carcinoma,' said Zachary Roberts, M.D., Ph.D., EVP, Research and Development and Chief Medical Officer at Allogene. 'Our proprietary Dagger technology allows the use of a standard cyclophosphamide and fludarabine-based lymphodepletion regimen with a single dose of ALLO-316. Strong CAR T-cell kinetics and extensive infiltration of tumor tissue by CAR T cells are combining to generate deep and durable remissions. These are results that were previously considered out of reach for patients with advanced solid tumors.' 'Patients diagnosed with advanced or metastatic renal cell carcinoma often face a median survival in months after exhausting standard therapies,' said Samer A. Srour, MB ChB, MS, Associate Professor of Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center and lead investigator of the TRAVERSE trial. 'These updated results from a larger cohort of patients with confirmed CD70 positive tumors provide compelling evidence that treatment with ALLO-316 can reduce tumor burden, control disease, and in some cases deliver durable responses. These findings underscore the clinical promise of an allogeneic CAR T to address the significant unmet needs in solid tumors and offer hope to patients who have exhausted other options.' In the Phase 1b expansion cohort, 22 patients whose tumors had progressed on multiple prior therapies were treated with lymphodepletion and 20 were treated with ALLO-316. All patients had tumors resistant to immune checkpoint blockers and at least one tyrosine kinase inhibitor (TKI), 82% had ≥2+ prior TKI, and 41% had prior belzutifan. Sixteen of the ALLO-316 treated patients had a high CD70 Tumor Proportion Score (TPS >50%). The Phase 1b expansion cohort evaluated the safety and efficacy of ALLO-316 at DL2 (80M CAR T cells) following a standard FC lymphodepletion regimen (fludarabine (30 mg/m2/day) and cyclophosphamide (500 mg/m2/day) for 3 days). The median time from enrollment to the start of therapy was four days. A single dose of ALLO-316 stabilized or reversed disease progression in the majority of patients. In the 16 patients with CD70 TPS ≥50%, the trial demonstrated a Confirmed Overall Response Rate (ORR) of 31% with 44% achieving a minimum of 30% reduction in tumor burden. Of the five confirmed responders, four maintain ongoing responses, with one in sustained remission for over 12 months. The median duration of response (mDOR) has not yet been reached, indicating the potential for long-term disease control. CD70+ patients Phase 1b(N=20) ORR (confirmed CR or PR per RECIST v1.1), n/N (%) 5/20 (25) CD70 TPS ≥50%CD70 TPS <50% 5/16 (31)0/4 (0) RECIST v1.1, Response Evaluation Criteria in Solid Tumors, version 1.1; TPS, tumor proportion score The safety profile of ALLO-316 was manageable and consistent with lymphodepletion and an active CAR T product. The most frequent Grade ≥3 events were hematologic and there were no treatment-related Grade 5 events. The most common all-grade adverse events were cytokine release syndrome (CRS) (68%; with no grade ≥3), neutropenia (68%), decreased white blood cell count (68%), anemia (59%), and thrombocytopenia (55%). Immune effector cell-associated neurotoxicity syndrome (ICANS) was 18% (with no grade ≥3) and no graft-versus-host disease (GvHD) occurred. Improved recognition of IEC-HS symptoms led to diagnosis in 36% of patients with 2 patients (9%) experiencing a short-term Grade 3 (one) or Grade 4 (one patient) event. Newly implemented diagnostic and management algorithms significantly mitigated IEC-HS, with no associated Grade 5 events. TEAEs ≥20% incidence in Phase 1b, n (%) Phase 1b (N=22a) All Grades Grade ≥3 Neutropenia 15 (68) 15 (68) White blood cell count decreased 15 (68) 15 (68) Anemia 13 (59) 9 (41) Thrombocytopenia 12 (55) 6 (27) Nausea 8 (36) 0 ALT increased 7 (32) 2 (9) Peripheral edema 7 (32) 0 Pyrexia 7 (32) 0 Arthralgia 6 (27) 0 AST increased 6 (27) 2 (9) Fatigue 5 (23) 0 Headache 5 (23) 0 AEs of Special Interest Any Grade Grade ≥3 CRS 15 (68) 0 Infection 10 (45) 8 (36) IEC-HS 8 (36) 2 (9)b ICANS 4 (18) 0 Graft-versus-host disease 0 0 IEC-HS includes the preferred terms immune effector cell-associated HLH-like syndrome and Hemophagocytic lymphohistiocytosis. a Includes 2 patients who received LD but did not receive ALLO-316 b One patient experienced G4 IEC-HS based on GI bleeding with subsequent improvement and 1 patient experienced G3 IEC-HS based on hypotension managed without pressors with subsequent improvement. About ALLO-316 (TRAVERSE)ALLO-316 is an AlloCAR T™ investigational product targeting CD70, which is highly expressed in renal cell carcinoma (RCC). CD70 is also selectively expressed in several cancers, creating the potential for ALLO-316 to be developed across a variety of both hematologic malignancies and solid tumors. The ongoing Phase 1 TRAVERSE trial is designed to evaluate the safety, tolerability, and activity of ALLO-316 in patients with advanced or metastatic clear cell RCC. In October 2024 the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation based on the potential of ALLO-316 to address the unmet need for patients with advanced or metastatic RCC. The FDA previously granted Fast Track Designation (FTD) to ALLO-316 in March 2023. In April 2024, the Company announced an award from the California Institute for Regenerative Medicine (CIRM) to support the ongoing TRAVERSE trial with ALLO-316 in RCC. About Allogene TherapeuticsAllogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of 'off-the-shelf' CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit and follow @AllogeneTx on X and LinkedIn. Cautionary Note on Forward-Looking Statements for Allogene This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release may, in some cases, use terms such as 'develop,' 'potential,' 'expect,' 'can,' 'enable,' 'showing,' 'generate,' 'may,' 'could,' 'designed to,' 'promise,' 'hope,' 'ongoing,' 'indicating,' 'mitigate,' 'evaluate,' 'pioneer,' 'goal' or 'will,' including alternative forms thereof, or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the potential of ALLO-316 to treat patients with advanced or metastatic RCC or to provide meaningful clinical benefit in patients with advanced RCC; the potential for ALLO-316 to be developed across a variety of both hematologic malignancies and solid tumors and to generate deep and durable remissions; the potential that ALLO-316 can reduce tumor burden, control disease, and deliver durable responses; the design and potential benefits of our Dagger technology; whether the Dagger® technology will become the next-generation allogeneic platform; ALLO-316 and the Dagger technology's ability to enable robust CAR T cell expansion and persistence and tumor infiltration; the potential of ALLO-316 to address the unmet need in solid tumors or offer hope to patients who have exhausted other options; the transformative potential of our AlloCAR T™ in solid tumors; the potential advantages of the RMAT and Fast Track designation; and our ability to deliver cell therapy on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene's expectations and actual results, including, risks and uncertainties related to: the limited nature of our Phase 1 data from our clinical trials and the extent to which such data may or may not be validated in any future clinical trials; the extent to which the Food and Drug Administration disagrees with our clinical or regulatory plans or the import of our clinical results, which could cause future delays to our clinical trials or require additional clinical trials; we may encounter difficulties enrolling patients in our clinical trials; we may not be able to demonstrate the safety and efficacy of our product candidates in our clinical trials, which could prevent or delay regulatory approval and commercialization; RMAT and Fast Track designations may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval and the designations can be revoked if the criteria for eligibility cease to be met; and challenges with manufacturing or optimizing manufacturing of our product candidates. These and other risks are discussed in greater detail in Allogene's filings with the Securities and Exchange Commission (SEC), including without limitation under the 'Risk Factors' heading in its Quarterly Report on Form 10-Q for the year ended March 31, 2025. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. AlloCAR T™ and Dagger® are trademarks of Allogene Therapeutics, Inc. Allogene's investigational AlloCAR T™ oncology products utilize Cellectis technologies. The anti-CD70 AlloCAR T program is licensed exclusively from Cellectis by Allogene and Allogene holds global development and commercial rights to this AlloCAR T™ program. Allogene Media/Investor Contact:Christine CassianoEVP, Chief Corporate Affairs & Brand Strategy while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Upturn
3 hours ago
- Business Upturn
StreetLeaf Plants its 10,000th Light in Advance of Hurricane Season
TAMPA, FLORIDA, June 01, 2025 (GLOBE NEWSWIRE) — StreetLeaf , the leading provider of solar-powered streetlight services in the United States, has installed its 10 thousandth solar-powered streetlight, just in time for hurricane season, which begins June 1st. The 10,000th light is part of the Shine On Florida initiative, and indeed marks a significant step in the company's mission to provide cost-effective, hurricane resilient infrastructure options to communities across Florida. Shine on Florida is a call to action for Florida's utility companies, local governments, home builders, municipalities, HOAs and residents to rethink current construction choices, and make Florida a model for climate-resiliency. 'Future proofing communities has been a focus of Streetleaf since our inception but our sense of urgency increased exponentially last year when three back-to-back hurricanes hit our local area,' said Liam Ryan, CEO of StreetLeaf. 'Shine On Florida represents expanding access to lighting solutions that enhance safety, improve quality of life, and reduce environmental impact for this hurricane season, as well as for future generations.' Streetleaf has been partnering with large real estate development companies, who have been an integral part of expanding the use of hurricane resilient streetlights across Florida. Those companies include Metro Development Group, D.R. Horton , and Forestar Group Inc. . Streetleaf is also working with more than 50 HOAs to bring these lights to their communities, including the innovative Babcock Ranch, America's first solar-powered town. Tampa Electric Company has played a critical role in helping integrate solar solutions into infrastructure discussions around the Tampa area, as StreetLeaf works to bridge utility-grade performance with forward-thinking innovation. In Manatee County, StreetLeaf installations are now helping neighborhoods stay illuminated during power outages, offering peace of mind in storm-prone seasons. Additionally, homebuilders like Lennar, Kotler, Homes by WestBay, and MI Homes have become early adopters of solar streetlighting, recognizing its value in offering safer, more sustainable communities to their homebuyers. The newly installed lighting systems feature StreetLeaf's solar panel technology, which captures energy even during cloudy conditions, and has 5-day battery backup. Each unit includes high-efficiency LED bulbs that provide superior illumination while consuming minimal power. The lights are equipped with motion sensors and smart controls that adjust brightness based on time of day and pedestrian activity, further optimizing energy usage. Streetleaf lights are DarkSky approved, ensuring minimal light pollution while maximizing visibility and safety for residents. This aligns with StreetLeaf's commitment to creating environmentally responsible lighting solutions that respect natural ecosystems. By choosing Streetleaf's solar lighting solutions, communities benefit from both cost savings and meaningful environmental impact. Each installation saves counties and HOAs tens of thousands of dollars annually in electricity costs, while eliminating the need for trenching and wiring can reduce upfront infrastructure expenses by hundreds of thousands of dollars. At the same time, Streetleaf helps neighborhoods reduce carbon emissions—just fifty solar streetlights can offset the electricity use of two average households each year. To learn more about the Shine On Florida program, and how Streetleaf is helping Florida communities shine brighter and greener, visit: For more information about StreetLeaf and its services, please visit: . ABOUT STREETLEAFHeadquartered in Tampa, Florida, StreetLeaf specializes in integrating modern, renewable technology into communities through one of the most essential yet often-overlooked features—streetlights. Since its founding in 2019, StreetLeaf has installed over 10,000 lights across the country, from Florida to California, and is rapidly growing to meet the rising demand for resilient, sustainable solutions. StreetLeaf uses high-quality, dependable and proprietary hardware, software, and service to partner with land developers, builders, municipalities, utilities, and HOAs to create safer, greener communities. A carbon-neutral certified company, StreetLeaf is also DarkSky approved, and has offset more than 4 million pounds of CO2 and counting, as a tree is planted for every StreetLeaf light that is installed in the ground. Learn more at
Yahoo
4 hours ago
- Yahoo
Avista issues all-source request for proposals for new energy and capacity resources along with Demand Response
Energy solutions sought to add capacity to Avista's portfolio SPOKANE, Wash., May 30, 2025 (GLOBE NEWSWIRE) -- Avista, through a request for proposal (RFP), is seeking proposals from bidders to add energy and capacity including distributed energy resources, to meet projected resource needs. In addition, Avista is seeking to add a Demand Response program to its portfolio to assist in addressing peak demand. The all-source RFP seeks resources to meet capacity needs for both Washington and Idaho up to 415 MW for winter and 425 MW for summer. As part of this RFP, Avista may bid repowering and/or self-build resources into the RFP. Avista is utilizing an Independent Evaluator for this RFP. Avista's 2025 Electric Integrated Resource Plan filed on December 31, 2024, reflects a need for new electric resources to meet growing customer demand for energy and clean energy requirements of the Clean Energy Transformation Act (CETA) to deliver carbon-neutral electric supply for Washington customers by 2030. 'This RFP represents Avista's efforts to meet its growing customer demand for energy in its service territory while also seeking resources that are clean, affordable and reliable. Avista is dedicated to partnering with innovative providers to deliver resilient energy solutions that support our customers and their evolving energy use.' said Scott Kinney, Avista's Vice President of Energy Resources & Integrated Planning. 'We're proud of our long-standing history of providing reliable power, and these additional resources will help ensure we continue to do so for years to come.' The RFP is open to parties who currently own, propose to develop, or hold rights to resources meeting Avista's requirements for energy and capacity. Bidders must also demonstrate an ability to meet the minimum requirements for eligibility as listed in the RFP. Avista will consider hybrid proposals including combinations of clean energy, capacity and/or storage. Avista will not accept proposals for Renewable Energy Certificates (REC) only. In addition, Avista seeks to acquire at least 5 MW of Demand Response (DR) beginning in 2026. DR programs provide a cost-effective solution to meeting energy demand at peak times and will be evaluated along with supply side resources. RFP responses are due by June 30, 2025. The RFP and bid instructions are available on the Avista website at: About Avista UtilitiesAvista Utilities is involved in the production, transmission and distribution of energy. We provide energy services and electricity to 422,000 customers and natural gas to 383,000 customers in a service territory that covers 30,000 square miles in eastern Washington, northern Idaho and parts of southern and eastern Oregon, with a population of 1.7 million. Avista Utilities is an operating division of Avista Corp. (NYSE: AVA). For more information, please visit To unsubscribe from Avista's news release distribution, send reply message to Contact: Media: Jared Webley, 24/7 Media Access (509) 495-4174
